Crystallography and the design of anti-AIDS drugs: Conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors

被引:205
作者
Das, K
Lewi, PJ
Hughes, SH
Arnold, E
机构
[1] Rutgers State Univ, Ctr Adv Biotechnol & Med, Dept Chem & Chem Biol, Piscataway, NJ 08854 USA
[2] Janssen Pharmaceut NV, Ctr Mol Design, Vosselaar, Belgium
[3] NCI, HIV Drug Resistance Program, NIH, Frederick, MD USA
关键词
TMC120-R147681; drug design; drug resistance; etravirine; TMC125-R165335;
D O I
10.1016/j.pbiomolbio.2004.07.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Drug resistance is a key cause of failure for treatment of HIV infection. The efficacy of non-nucleoside reverse transcriptase inhibiting (NNRTI) drugs is impaired by rapid emergence of drug-resistance mutations. A multidisciplinary effort led to the discovery of the potent NNRTIs dapivirine and etravirine, both of which are diarylpyrimidine (DAPY) derivatives. Systematic structural and molecular modeling studies of HIV-1 reverse transcriptase (RT)/NNRTI complexes revealed different modes of inhibitor binding, and some of the DAPY inhibitors can bind to RT in different conformations. The torsional flexibility ("wiggling") of the inhibitors can generate numerous conformational variants and the compactness of the inhibitors permits significant repositioning and reorientation (translation and rotation) within the pocket ("jiggling"). Such adaptations appear to be critical for the ability of the diarylpyrimidine NNRTIs to retain their potency against a wide range of drug-resistant HIV-1 RTs. Exploitation of inhibitor conformational flexibility (such as torsional flexibility about strategically located chemical bonds)
引用
收藏
页码:209 / 231
页数:23
相关论文
共 64 条
[1]  
ANDRIES K, 2000, P 40 ICAAC TOR CAN
[2]   Recent developments for the efficient crystallographic refinement of macromolecular structures [J].
Brünger, AT ;
Adams, PD ;
Rice, LM .
CURRENT OPINION IN STRUCTURAL BIOLOGY, 1998, 8 (05) :606-611
[3]  
Coffin J. M., 1997, RETROVIRUSES
[4]   HIV POPULATION-DYNAMICS IN-VIVO - IMPLICATIONS FOR GENETIC-VARIATION, PATHOGENESIS, AND THERAPY [J].
COFFIN, JM .
SCIENCE, 1995, 267 (5197) :483-489
[5]  
COHEN J, 2002, THERAPIES, V296, P2322
[6]   Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant [J].
Das, K ;
Ding, JP ;
Hsiou, Y ;
Clark, AD ;
Moereels, H ;
Koymans, L ;
Andries, K ;
Pauwels, R ;
Janssen, PAJ ;
Boyer, PL ;
Clark, P ;
Smith, RH ;
Smith, MBK ;
Michejda, CJ ;
Hughes, SH ;
Arnold, E .
JOURNAL OF MOLECULAR BIOLOGY, 1996, 264 (05) :1085-1100
[7]   Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants [J].
Das, K ;
Clark, AD ;
Lewi, PJ ;
Heeres, J ;
de Jonge, MR ;
Koymans, LMH ;
Vinkers, HM ;
Daeyaert, F ;
Ludovici, DW ;
Kukla, MJ ;
De Corte, B ;
Kavash, RW ;
Ho, CY ;
Ye, H ;
Lichtenstein, MA ;
Andries, K ;
Pauwels, R ;
de Béthune, MP ;
Boyer, PL ;
Clark, P ;
Hughes, SH ;
Janssen, PAJ ;
Arnold, E .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (10) :2550-2560
[8]  
De Clercq E, 2002, MED RES REV, V22, P531
[9]   Highlights in the Development of New Antiviral Agents [J].
De Clercq, E. .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2002, 2 (02) :163-175
[10]   Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation [J].
Di Fabio, S ;
Van Roey, J ;
Giannini, G ;
van den Mooter, G ;
Spada, M ;
Binelli, A ;
Pirillo, MF ;
Germinario, E ;
Belardelli, F ;
de Bethune, MP ;
Vella, S .
AIDS, 2003, 17 (11) :1597-1604